17
Views
0
CrossRef citations to date
0
Altmetric
Drug Profile

The cost–effectiveness of clopidogrel: a review by indication

Pages 123-130 | Published online: 09 Jan 2014
 

Abstract

Clopidogrel is a thienopyridine that acts by inhibiting the adenosine diphosphate-dependent activation of platelets. It has proven efficacy in two general categories: long-term secondary prophylaxis in populations with existing vascular disease, and of limited duration following cardiovascular events or procedures. Clopidogrel may be used alone or in combination with aspirin, depending on the indication. The cost–effectiveness of clopidogrel varies with the indication, the population in which it is used, the risk of future events faced by that population and whether it is combined with aspirin. This article will review existing data on the cost–effectiveness of clopidogrel for each indication with a particular focus on these four criteria.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.